Hologic Inc
$ 75.35
-0.12%
24 Feb - close price
- Market Cap 16,821,504,000 USD
- Current Price $ 75.35
- High / Low $ 75.48 / 75.33
- Stock P/E 31.27
- Book Value 23.51
- EPS 2.41
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.11 %
- 52 Week High 75.49
- 52 Week Low 51.90
About
Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Analyst Target Price
$76.60
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-29 | 2025-11-03 | 2025-07-30 | 2025-05-01 | 2025-02-05 | 2024-11-04 | 2024-07-29 | 2024-05-02 | 2024-02-01 | 2023-11-09 | 2023-07-31 | 2023-05-01 |
| Reported EPS | 1.04 | 1.13 | 1.08 | 1.03 | 1.03 | 1.01 | 1.06 | 1.03 | 0.98 | 0.89 | 0.93 | 1.06 |
| Estimated EPS | 1.1 | 1.1 | 1.05 | 1.02 | 1.02 | 1.01 | 1.01 | 0.98 | 0.95 | 0.84 | 0.89 | 0.88 |
| Surprise | -0.06 | 0.03 | 0.03 | 0.01 | 0.01 | 0 | 0.05 | 0.05 | 0.03 | 0.05 | 0.04 | 0.18 |
| Surprise Percentage | -5.4545% | 2.7273% | 2.8571% | 0.9804% | 0.9804% | 0% | 4.9505% | 5.102% | 3.1579% | 5.9524% | 4.4944% | 20.4545% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HOLX
2026-02-24 17:50:32
Hologic, Inc. has had its stock evaluation revised due to current market dynamics. While the stock has shown stability and outperformed the S&P 500 year-to-date and over the past year, its longer-term performance over three and five years has lagged behind the broader market. Technical indicators present a mixed picture, with some showing bullish momentum and others a bearish or neutral trend.
2026-02-23 04:51:02
The global Biopsy Devices Market is projected to grow at a CAGR of 7.2% during the forecast period (2024-2031), driven by rising cancer prevalence and advancements in minimally invasive procedures. Key developments include AI integration in imaging, disposable vacuum-assisted needles, and robotic-assisted biopsy systems in various regions. Major players in this market include Becton, Dickinson and Company, Hologic Inc., and Devicor Medical Products Inc.
2026-02-22 12:00:00
This article provides a detailed analysis of Hologic Inc. (NASDAQ: HOLX), highlighting its neutral near and mid-term readings and a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels to assist in tactical trading decisions.
2026-02-22 11:59:00
The non-invasive aesthetic treatment market is projected to reach US$ 150 billion by 2030, growing at a CAGR of 15.7% from 2021 to 2030, up from US$ 49 billion in 2020. This growth is driven by an increasing focus on physical appearance, particularly among adults and those aged 50+, with injectables dominating the market by procedure and medspas by end-use. North America currently leads the market, while Asia Pacific is expected to show the highest CAGR.
2026-02-22 09:10:14
The global C-arms market size was valued at USD 2.33 billion in 2024 and is projected to reach USD 3.7 billion by 2033, growing at a CAGR of 5.25%. This growth is primarily driven by the increasing geriatric population, the prevalence of chronic illnesses, and advancements in imaging technologies, with North America leading the market. However, the high cost of equipment and procedures poses a significant restraint, while continued technological innovation and public-private funding present substantial opportunities for market expansion.
2026-02-22 05:14:00
American tennis player Coco Vandeweghe revealed how her boyfriend, Kyle Filippelli, played an unexpected role in securing the new partnership between Hologic and the WTA. She explained that Filippelli was golfing with Steve McMillan, chairman of Hologic, who expressed admiration for the WTA's stance against China and interest in getting involved. Vandeweghe described the partnership as "organic" and a great fit, given Hologic's focus on women's health and the WTA's platform.
